A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: NFE2L2 Gene Mutation
Squamous Non-Small Cell Neoplasm of Lung
Non-Small Cell Lung Cancer
Squamous Non-small-cell Lung Cancer

Interventions: Drug: sapanisertib

Registration Number: NCT05275673

Lead Sponsor: Faeth Therapeutics

Brief Summary: This is a multicenter, randomized, open-label Phase 2 study of sapanisertib in biomarker-defined populations of sqNSCLC. Patients with NFE2L2 (the name for gene encoding the protein called NRF2)-mutated or wild-type sqNSCLC should have disease that has progressed on or after at least two prior systemic therapies for metastatic disease including platinum-doublet chemotherapy and a programmed cell death 1 ligand 1 (PD-L1) inhibitor. The study will evaluate sapanisertib monotherapy in patients with relapsed/refractory sqNSCLC as two separate groups: Group A: NFE2L2-mutated sqNSCLC and Group B: NFE2L2-WT sqNSCLC.

Detailed Description: NFE2L2 mutation status for all patients will be identified using local or central next generation sequencing (NGS) testing on archival or fresh tissue or circulating tumor deoxyribonucleic acid (ctDNA), the results of which must be reviewed and approved by the Sponsor prior to enrollment. Each group will be randomized 1:1 to one of two doses/schedules of sapanisertib. Approximately 30 NFE2L2-mutant and 20 NFE2L2-wild type patients will be enrolled. Patients will be treated with sapanisertib until disease progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), unacceptable toxicity, withdrawal of consent, or death.

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 7

Inclusion Criteria

Stage IV squamous NSCLC.
Disease progression during or after prior systemic therapy for metastatic disease, which must include platinum-doublet chemotherapy and immune checkpoint inhibitor therapy (anti-PD-(L)1 +/-anti-CTLA-4), if approved and available, administered as separate lines of therapy or in combination.
Has study-eligible mutation in NFE2L2 or wild-type NFE2L2 using NGS from a College of American Pathologists- (CAP)-accredited and/or a Clinical Laboratory Improvement Amendments- (CLIA)-certified laboratory
Must have at least one radiographically measurable lesion per RECIST v1.1 defined as a lesion that is ≥ 10 mm in longest diameter or lymph node that is ≥ 15 mm in short axis imaged by computerized tomography (CT) scan or Magnetic Resonance Imaging (MRI).
Target lesions situated in a previously irradiated area may be considered measurable if progression has been demonstrated subsequent to radiation therapy.
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
Adequate Organ Function Laboratory Findings: Absolute neutrophil count (ANC): ≥1,500/mm3, Hemoglobin: ≥9.0 g/dL * Transfusions and growth factors must not be used within 2 weeks prior to randomization to meet these requirements, Platelets: ≥ 100,000/mm3, Calculated creatinine clearance (CrCl): ≥ 40mL/min, Serum total bilirubin: ≤ 1.5× upper limit of normal (ULN) OR ≤ 3 mg/dL for patients with Gilbert's disease, AST (SGOT) and ALT (SGPT): ≤ 2.5× ULN OR ≤ 5× ULN for patients with liver metastases, Fasting triglycerides: < 300 mg/dL, Fasting serum glucose: <160 mg/dL
A female patient of childbearing potential must:
1. Have a negative serum or urine pregnancy test within 7 days prior to the first dose of study treatment
2. Agree to use acceptable methods of contraception(See Section 8.1.2) during the study and for a minimum of 14 days following the last dose of sapanisertib
3. Post-menopausal females (no menses for >1 year without an alternative medical cause) and surgically sterilized females are exempt from these requirements.
Male patients must use an effective barrier method of contraception if sexually active with a female of childbearing potential and refrain from donating sperm during the study and for a minimum of 14 days following the last dose of sapanisertib.

Exclusion Criteria

Non-squamous cell histology and mixed histology tumors with any small-cell/neuroendocrine component.
Prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment per investigator's discretion.
Receipt before the first dose of study drug of any of the following:

i. Any investigational agent within 4 weeks. ii. Chemotherapy with 3 weeks (6 weeks for nitrosoureas or mitomycin C) iii. Any radiotherapy within 2 weeks prior to randomization with the exception of palliative radiotherapy for isolated tumor lesions
Major surgery or other anticancer therapy not previously specified within 4 weeks.
Unable or unwilling to discontinue proton pump inhibitor (PPI) use ≥ 5 days prior to randomization.
Interstitial lung disease or a history of pneumonitis that required oral or intravenous glucocorticoid treatment.
Any condition including social, psychiatric or medical (including uncontrolled significant concurrent illness) that in the opinion of the Investigator could interfere with treatment or protocol-related procedures.
Patients who are pregnant or lactating.
Symptomatic ascites or pleural effusion. Exception: Patients who are clinically stable following treatment for these conditions (including therapeutic thoraco-or paracentesis) are eligible.
Refractory nausea and vomiting, uncontrolled diarrhea, malabsorption, significant small bowel resection or gastric bypass surgery, use of feeding tubes or other situation that may preclude adequate absorption of oral study medication.
Infection requiring more than 5 days of parenteral antibiotics, antivirals, or antifungals within two weeks prior to randomization.
Patients receiving systemic corticosteroids greater than prednisone 10 mg or equivalent (excluding inhalers or low-dose hormone replacement therapy) within the 7 days before treatment initiation.
Previous intolerance to mammalian target of rapamycin (mTOR), AKT, or dual PI3K/mTOR inhibitors.
Patients with symptomatic, active/untreated central nervous system metastasis and/or leptomeningeal disease are not eligible.
Significant active cardiovascular disease
Participants who are known to be HIV-positive, unless assessed to be healthy with a low risk of AIDS-related outcomes.
Known active Hepatitis B or C infection.
Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of the study drug.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group B - NFE2L2 Wild-Type, Dosing Cohort 2	sapanisertib	sapanisertib 2 mg BID
Group B - NFE2L2 Wild-Type, Dosing Cohort 1	sapanisertib	sapanisertib 3 mg QD
Group A - NFE2L2 Mutation, Dosing Cohort 2	sapanisertib	sapanisertib 2 mg twice daily (BID)
Group A - NFE2L2 Mutation, Dosing Cohort 1	sapanisertib	sapanisertib 3 mg once daily (QD)

Primary Outcome Measures

Name	Time	Method
Investigator-Assessed Overall Response Rate (ORR) Per RECIST v1.1.	36 months	ORR is defined as the percentage of participants with complete response (CR) or partial response (PR) according to the RECIST v1.1 criteria as assessed by the investigator.
Number of Participants With Adverse Events (AEs), Serious AEs, and Deaths	From the first dose through 28 days after the last dose of sapanisertib (up to a maximum of 124 days).	An adverse event (AE) is defined as any untoward, undesired, or unplanned medical occurrence in a patient administered a medicinal product whether or not considered drug related. A serious adverse event (SAE) is defined as an AE that occurs after receiving study treatment (or after signing informed consent and before receiving study treatment if due to a protocol-mandated procedure) that either results in death, is life-threatening, requires inpatient hospitalization, results in persistent or significant disability, results in congenital anomaly or birth defect, or otherwise meets criteria as an important medical event. Events were categorized as related or not related to study drug, and event severity was graded as mild (1), moderate (2), severe (3), life-threatening (4), or fatal (5).

Secondary Outcome Measures

Name	Time	Method
Duration of Response (DOR)	36 months	DOR is the time between the first documentation of partial response (PR) or a complete response (CR) to the first documentation of progressive disease or death, whichever occurs first.
Progression-Free Survival (PFS)	36 months	PFS is defined as the time from randomization to the first occurrence of disease progression as determined by the investigator using RECIST v1.1 or death from any cause, whichever occurs first.
Overall Survival (OS) at 6 and 12 Months	Months 6 and 12	OS is defined as the time from randomization to death due to any cause.

Trial Locations

Locations (13): Memorial Sloan Kettering Cancer Center - Thoracic
🇺🇸
New York, New York, United States
UC Davis Comprehensive Cancer Center
🇺🇸
Davis, California, United States
Providence Medical Group Santa Rosa - Cancer Center
🇺🇸
Santa Rosa, California, United States
Ocala Oncology Center
🇺🇸
Ocala, Florida, United States
Washington University - Patient Care Coordinator Center
🇺🇸
Saint Louis, Missouri, United States
Providence Cancer Institute Franz Clinic
🇺🇸
Portland, Oregon, United States
Tennessee Oncology
🇺🇸
Nashville, Tennessee, United States
Virginia Cancer Specialist, PC
🇺🇸
Fairfax, Virginia, United States
UPMC Cancer Pavilion
🇺🇸
Pittsburgh, Pennsylvania, United States
Florida Cancer Specialists
🇺🇸
Tallahassee, Florida, United States
Norton Cancer Institute, Downtown
🇺🇸
Louisville, Kentucky, United States
Karmanos Cancer Institute
🇺🇸
Detroit, Michigan, United States
Zangmeister Cancer Center
🇺🇸
Columbus, Ohio, United States